READING, Pa., Dec. 5, 2017 /PRNewswire/ -- With new products such as Genentech's Hemlibra (Emicizumab-kxwh) entering the United States marketplace, PFI interviewed personnel in critical business positions across multiple Hemophilia organizations to gain a full understanding on how they are penetrating such a specialized market.
Joyce Wedemeyer, Director of Marketing and Sales at PFI, says that commercial operations approaches are evolving within the Hemophilia space.
"We have been noticing that hemophilia organizations are starting to focus more on deploying ultra-specialized Market Access account teams with expertise in hemophilia," Wedemeyer said.
"However, efforts to target non-hemophilia-specific channels, such as community hospitals, have been generally unsuccessful."
Additional industry insights captured in this report include:
- Strategic Overview of the Hemophilia Franchise
- Number of Key Sales and Marketing Personnel by Type
- Structure of the Sales and Marketing Organization
- Market Access Teams
- Management of the Product Portfolio
- Approach to Field Reimbursement
- Response to Biosimilar Developments
- Typical Compensation Package for Hemophilia Sales Representatives
For more information on the report mentioned above, please contact Joyce Wedemeyer at firstname.lastname@example.org or by phone at 610-370-2906.
PharmaForce International (PFI) is a competitive intelligence firm with over two decades of experience in the pharmaceutical and biotech industries. PFI has become the market leader in commercial operations benchmarking and competitive intelligence. The globally focused company employs marketplace experts uniquely qualified to perform primary research required by clients in most major pharmaceutical markets around the world, including Europe, India, Japan, Latin America, and the United States.
SOURCE PharmaForce International